|
EFFICACY AND SAFETY OF NARROW BAND UVB HOME PHOTOTHERAPY |
|
Poster presented at American Academy of Dermatology
56th annual convention, Feb 2-6, 2007
Christopher B. Yelverton, MD, MBA1;
Ann Boles, RN1;
Adele Clark, PA-C1;
Mandeep Kaur, MBBS1;
Fabian Camacho, MA, MS1;
Steven R. Feldman, MD, PhD1-3
Departments of Dermatology1,
Pathology2,
and Public Health Sciences3,
Wake Forest University Health Sciences, Winston Salem, NC
<read full poster> |
INTRODUCTION:
While effective and relatively safe compared to other treatments for severe
psoriasis, office UVB phototherapy is quite inconvenient, requiring visits 3-5
times per week. Home-based phototherapy devices offer greater convenience and
are more of cost-effective.
PURPOSE:
To explore efficacy, safety, and adherence to a
self-administered home phototherapy regimen in a clinical trial setting.
METHODS:
We conducted a clinical trial of self-administered
narrow-band UVB (NBUVB) in combination with low-dose (10-25mg/day) acitretin in
the treatment of moderate to severe psoriasis. Subjects were provided with a [Panosol-II]
6-foot, 6-bulb, single panel NBUVB unit and instructed on its use.
Dosage recommendations were based on skin types, manufacturer recommendations,
and published protocols. Subjects were to self-treat 3 times weekly and adjust
dosage upward as tolerated over the 12 week study period.
TABLE 1. SEVERITY OUTCOME MEANS FROM BASELINE TO
WEEK 12
|
Baseline |
Week 2 |
Week 4 |
Week 8 |
Week 12 |
|
PASI |
18.56 |
17.70 |
15.36** |
13.98 |
|
PGA |
3.40 |
3.08** |
2.78*** |
2.61*** |
|
SGA |
4.04 |
3.63** |
3.50 *** |
2.68*** |
Note: T-tests for significant mean change from baseline results:
**
p value <.05.*** p-value < .001
Discussion:
UVB
phototherapy for psoriasis is a safe and effective treatment option.
Although home phototherapy can be used in cases where patients have limited
access to office-based phototherapy, its usage is poorly studied.
This study provides
preliminary clinical trial data for home phototherapy in conjunction with
low-dose acitretin. The combined treatment showed significant reductions in PASI
score, PGA, and SGA at weeks 8 and 12. UVB treatment was well tolerated.<read
full poster>
Consider our unique
contracting opportunities.
Call us for details.
Contact us |
